Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 6/20 | 0.47 |
| ▸ | HPGDS | O60760 | 7/20 | 0.45 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19065641 | 0.85 | NPY5R (0.53) | NPY5RSCN2AHPGDS | |
| SCHEMBL19065340 | 0.82 | NPY5R (0.50) | NPY5RSCN2AHPGDSSMPD3CYP3A4 | |
| SCHEMBL19065711 | 0.81 | L3MBTL1 (0.54) | NPY5RSCN2AHPGDS | |
| SCHEMBL19066083 | 0.81 | NPY5R (0.48) | NPY5RSCN2AHPGDSSMPD3CYP3A4 | |
| SCHEMBL19065252 | 0.81 | NPY5R (0.48) | NPY5RSCN2AHPGDSSMPD3CYP3A4 | |
| SCHEMBL19065511 | 0.80 | NPY5R (0.47) | NPY5RSCN2AHPGDS | |
| SCHEMBL19065477 | 0.79 | NPY5R (0.46) | NPY5RSCN2AHPGDSSMPD3CYP3A4 | |
| SCHEMBL19065720 | 0.78 | NPY5R (0.45) | NPY5RSCN2AHPGDS | |
| SCHEMBL19065362 | 0.78 | ALK (0.52) | NPY5R | |
| SCHEMBL19065354 | 0.78 | NPY5R (0.45) | NPY5RSCN2AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885SCN2A 1369/4885HPGDS 700/4885 |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885SCN2A 1369/4885HPGDS 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.